REFERENCES
- All references are to the Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA, USA.
- E DeJesus E and others. The Context Study: Efficacy and Safety of GW433908/RTV in Fl-experienced Subjects with Virological Failure (24 Week Results). Abstract 178 (oral session).
- J Gathe and others. Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor Experienced Pa-tients: BI 1182.52. Abstract 179 (oral session).
- J Nadler and others. The NEAT Study: GW433908 Efficacy and Safety in ART-naïve Subjects, Final 48-week Analysis. Ab-stract 177 (oral session).
- S Staszewski and others. Efficacy and Safety of Tenofovir DF (TDF) Versus Stavudine (d4T) When Used in Combination with Lamivudine and Efavirenz in Antiretroviral Naive Pa-tients: 96-Week Preliminary Interim Results. Abstract 564b (poster).
- F Van Leth and others. Results of the 2NN Study: A Random-ized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine. Abstract 176 (oral session).
- F Van Leth and others. Lipid Changes in a Randomized Com-parative Trial of First-line Antiretroviral Therapy with Regi-mens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine (2NN Study). Abstract 752 (poster).
REFERENCES
- Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Robinson P, Hall D, Myers M, Lange JMA. A randomized, double-blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients. The INCAS Trial. JAMA. 1998;279(12):930–937.
- Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl J Med. 1997;337(11):734–739.
- Gatell J, Murphy R, Katlama C, et al. The Atlantic study. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. October 23, 1999. Lisbon. Abstract #1243.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865–1873.
- US DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002. http://www.aidsinfo.nih.gov/guidelines/adult/html_adult_02-04-02.html.
- BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. July 27, 2001. http://www.aidsmap.com/about/bhiva/bhivagd.asp.
- Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fisch! MA, Gate JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katsenstein DA, Montaner JSGM, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA panel. JAMA. 2002;288(2):222–235.
- Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens contain-ing nevirapine or efavirenz in combination with 2 nucleo-side analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. J Infect Dis. 2002185: 1062–1069.
- Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53–61.
- van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. 10th Conference on Retro viruses and Opportunistic Infections. February 10–14, 2003. Boston. Abstract 176.
- van Leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN study). 10th Conference on Retroviruses and Opportunistic Infections. February 10–14, 2003. Boston. Abstract 752.
REFERENCES
- J Lange, F van Leth and others. Results of the 2NN Study: A randomized comparative trial of 1St line antiretroviral therapy (ART) with regimens containing either nevirapine (NVP) alone, efavirenz (EFV) alone or both drugs combined, together with stavudine and lamivudine. (2NN Study). Ab-stract 176.
- F van Leth, P Phanuphak and others. 2 NN Substudy of Lipids. Abstract 752.
REFERENCES
- J Nadler and others. The NEAT Study: GW 433908 efficacy and safety in HAART-naive subjects. Final 48-week analysis. Abstract 177.
REFERENCES
- E DeJesus. The Context Study: Efficacy and Safety of GW433908/RTV in P1-experienced Subjects with Virologi-cal Failure (24 Week Results). Abstract 178. 10th Confer-ence on Retroviruses and Opportunistic Infections. Febru-ary 10–14, 2003. Boston, MA, USA.
REFERENCES
- J Gathe and others. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. Abstract 179. 10th Conference on Retro viruses and Opportunistic Infections. February 10–14, 2003. Bos-ton, MA, USA.
REFERENCES
- Sterne JAC and others. Does It Matter Where You Came From? Prognosis of Patients Starting Potent Therapy, According to Initial Response. Abstract 181 (poster). 10th Conference on Retro viruses and Opportunistic Infections. February 10–14, 2003. Boston, MA, USA.
REFERENCES
- All references are to the Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. February 10–14, 2003. Boston, MA, USA.
- J Ananworanich and others. HIV-NAT 001.4: A Prospective Randomized Trial of Structured Treatment Interruption in Patients with Chronic HIV Infection. Abstract 64 (oral ses-sion).
- SG Deeks and others. Continued Reverse Transcriptase Inhibi-tor Therapy is Sufficient to Maintain Short-Term Partial Suppression of Multi-drug Resistant Viremia. Abstract 640 (poster).
- C Katlama and others. Long-term Benefit of Treatment Inter-ruption in Salvage Therapy (GIGHAART ANRS 097). Ab-stract 68 (oral session).
- J Lawrence and others. CPCRA 064: A Randomized Trial Ex-amining Structured Treatment Interruption for Patients Failing Therapy with Multi-drug Resistant HIV. Abstract 67 (oral session).
- L Ruiz and others. A Multi-center, Randomized Controlled Clini-cal Trial of Continuous vs Intermittent HAART Guided by CD4 + T-cell Counts and Plasma HIV-1 RNA Levels. Ab-stract 65 (oral session).
REFERENCES
- SJ Little and others. High Replication Capacity is Associ-ated with High Baseline Viral Load in Untreated Subjects with Primary HIV Infection. Abstract 152.
- D Linden and others. Viral and Immune Correlates of Dis-cordant CD4NL Responses to NNRTI-based HAART and Comparison to a Discordant Cohort Receiving Protease Inhibitor-Based HAART. Abstract 146.
- ML Greenberg and others. Baseline and On-treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks. Abstract 141.
- J Whitcomb and others. Analysis of Baseline Enfuvirtide (T20) Susceptibility and Co-receptor Tropism in Two-phase III Study Populations. Abstract 557.
- NT Parkin and others. Distribution of Phenotypic Drug Susceptibility Among More than 2,000 Wild-type Viruses. Abstract 585.
- SG Deeks and others. Continued Reverse Transcriptase Inhibitor Therapy is Sufficient to Maintain Short-Term Par-tial Suppression of Multi-drug Resistant Viremia. Abstract 640.
- C Katlama and others. Long-term Benefit of Treatment Interruption in Salvage Therapy (GIGHAART ANRS 097). Abstract 68.
- MD Miller and others. Decreased Replication Capacity of HIV-1 Clinical Isolates Containing K65R or M184V RT Mu-tations. Abstract 616.
- SH Eshleman and others. Extended Analysis of Nevirapine Resistance in Women with Subtype A vs D HIV-1 6–8 Weeks After Single Dose NVP Prophylaxis: HIVNET 012. Abstract 857.